Subclinical diastolic dysfunction represents the early phase of diabetic cardiomyopathy and
is a common complication among type 2 diabetic patients that increases mortality rate among
those patients and can progress to heart failure with preserved ejection fraction.
Trimetazidine is an anti-ischemic agent widely used in the treatment of coronary artery
disease and it has positive effects on energy metabolism in heart failure.
Therefore, we hypothesized that trimetazidine may have potential benefit on the amelioration
of the inflammatory insult and improving the clinical outcomes in patients with diabetic
cardiomyopathy especially if applied in the early stages.